These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4084732)

  • 1. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
    Merrick MV; Ding CL; Chisholm GD; Elton RA
    Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
    Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
    Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.
    Reikerås O; Due J; Sundsfjord JA
    Int Urol Nephrol; 1988; 20(1):51-4. PubMed ID: 3283071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone scanning and plasma phosphatases in carcinoma of the prostate.
    O'Donoghue EP; Constable AR; Sherwood T; Stevenson JJ; Chisholm GD
    Br J Urol; 1978 May; 50(3):172-7. PubMed ID: 753455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
    Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
    Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone imaging and serum phosphatases in prostatic carcinoma.
    Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
    Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].
    Kida T; Higuchi Y
    Kaku Igaku; 1981 Aug; 18(7):907-15. PubMed ID: 7321322
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis.
    Imai K; Tomaru Y; Ohnuki T; Yamanaka H; Sakai H; Kanetake H; Minami Y; Nomata K; Saito Y
    Cancer; 1992 Jun; 69(12):2983-9. PubMed ID: 1591692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
    Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
    Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bone scanning in the assessment of prostatic carcinoma.
    McGregor B; Tulloch AG; Quinlan MF; Lovegrove F
    Br J Urol; 1978 May; 50(3):178-81. PubMed ID: 753456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer.
    Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM
    Prostate; 1981; 2(2):187-206. PubMed ID: 7301655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Audit and its impact in the management of advanced prostatic cancer.
    Rana A; Chisholm GD; Christodoulou S; McIntyre M; Elton RA
    Br J Urol; 1993 Oct; 72(4):478-83. PubMed ID: 8261306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phosphatases and bone scan in prostatic cancer].
    Urrutia M; Montero J; Grade J; Llopis M
    Actas Urol Esp; 1977; 1(4):207-12. PubMed ID: 567001
    [No Abstract]   [Full Text] [Related]  

  • 17. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
    Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
    Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment.
    Fosså SD; Heilo A; Lindegaard M; Skinningrud A; Ous S
    Eur Urol; 1983; 9(5):262-6. PubMed ID: 6628467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.
    Gerber G; Chodak GW
    Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy--comparison with tumor markers and bone X-ray.
    Koizumi K; Uchiyama G; Komatsu H
    Ann Nucl Med; 1994 Nov; 8(4):225-30. PubMed ID: 7535550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.